June 2021
Volume 62, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2021
Characterization of macular neovascularization in geographic atrophy
Author Affiliations & Notes
  • Riccardo Sacconi
    Ophthalmology, IRCCS Ospedale San Raffaele, Milano, Lombardia, Italy
  • Maria Brambati
    Ophthalmology, IRCCS Ospedale San Raffaele, Milano, Lombardia, Italy
  • Alexandra Miere
    Universite Paris-Est Creteil Val de Marne, Creteil, Île-de-France, France
  • Eliana Costanzo
    IRCSS Fondazione G B Bietti per lo Studio e la Ricerca in Oftalmologia ONLUS, Roma, Lazio, Italy
  • Vittorio Capuano
    Universite Paris-Est Creteil Val de Marne, Creteil, Île-de-France, France
  • Enrico Borrelli
    Ophthalmology, IRCCS Ospedale San Raffaele, Milano, Lombardia, Italy
  • Marco Battista
    Ophthalmology, IRCCS Ospedale San Raffaele, Milano, Lombardia, Italy
  • Maria Cristina Parravano
    IRCSS Fondazione G B Bietti per lo Studio e la Ricerca in Oftalmologia ONLUS, Roma, Lazio, Italy
  • Eric H Souied
    Universite Paris-Est Creteil Val de Marne, Creteil, Île-de-France, France
  • Francesco Bandello
    Ophthalmology, IRCCS Ospedale San Raffaele, Milano, Lombardia, Italy
  • Giuseppe Querques
    Ophthalmology, IRCCS Ospedale San Raffaele, Milano, Lombardia, Italy
  • Footnotes
    Commercial Relationships   Riccardo Sacconi, Carl Zeiss Meditec (Dublin, USA) (C), Novartis (Basel, Switzerland) (C); Maria Brambati, None; Alexandra Miere, None; Eliana Costanzo, None; Vittorio Capuano, None; Enrico Borrelli, Carl Zeiss Meditec (Dublin, USA) (C), Centervue (Padova, Italy) (C), Novartis (Basel, Switzerland) (C); Marco Battista, None; Maria Cristina Parravano, Allergan Inc (Irvine, California,USA) (C), Bayer Shering-Pharma (Berlin, Germany) (C), Novartis (Basel, Switzerland) (C), Zeiss (Dublin, USA) (C); Eric Souied, Allergan Inc (Irvine, California,USA) (C), Bayer Shering-Pharma (Berlin, Germany) (C), Novartis (Basel, Switzerland) (C), Roche (Basel, Switzerland) (C); Francesco Bandello, Alcon (Fort Worth,Texas,USA) (C), Alimera Sciences (Alpharetta, Georgia, USA) (C), Allergan Inc (Irvine, California,USA) (C), Bausch And Lomb (Rochester, New York, USA) (C), Bayer Shering-Pharma (Berlin, Germany) (C), Farmila-Thea (Clermont-Ferrand, France) (C), Genentech (San Francisco, California, USA) (C), Hoffmann-La-Roche (Basel, Switzerland) (C), Novagali Pharma (Évry, France) (C), Novartis (Basel, Switzerland) (C), Sanofi-Aventis (Paris, France) (C), Thrombogenics (Heverlee,Belgium) (C), Zeiss (Dublin, USA) (C); Giuseppe Querques, Alimera Sciences (Alpharetta, Georgia, USA) (C), Allergan Inc (Irvine, California, USA) (C), Bayer Shering-Pharma (Berlin, Germany) (C), Heidelberg (Germany) (C), Novartis (Basel, Switzerland) (C), Sandoz (Berlin, Germany) (C), Zeiss (Dublin, USA) (C)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2021, Vol.62, 237. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Riccardo Sacconi, Maria Brambati, Alexandra Miere, Eliana Costanzo, Vittorio Capuano, Enrico Borrelli, Marco Battista, Maria Cristina Parravano, Eric H Souied, Francesco Bandello, Giuseppe Querques; Characterization of macular neovascularization in geographic atrophy. Invest. Ophthalmol. Vis. Sci. 2021;62(8):237.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To characterize macular neovascularization (MNV) developing in eyes affected by geographic atrophy (GA).

Methods : In this multicentric longitudinal study, patients previously affected by GA that developed an active MNV were included in 3 retina referral centers. Patients were investigated using structural optical coherence tomography (OCT), fundus autofluorescence, OCT-angiography, and dye angiographies. Patients were treated with ProReNata (PRN) anti-vascular endothelial growth factor (VEGF) injections and were revaluated after treatment.

Results : Among 512 patients previously diagnosed with GA, 40 eyes of 40 patients (mean age 80.8±7.9 years, mean GA area 8.73±7.39 mm2) presented with treatment-naïve exudative MNV (accounting for an estimated prevalence of 7.81%; 5.49 - 10.13, 95% confidence intervals) and thus were included in the analysis. 67.5% of MNVs were classified as type 2 MNV, 25% as type 1, 2.5% as type 3, and 5% as mixed phenotype. In 92.5% of cases, active MNV in GA showed subretinal hyperreflective material (SHRM) with or without evidence of sub-/intra-retinal hyporeflective exudation. During a mean follow-up of 28±25 months, patients were treated with 6.6±6.3 anti-VEGF injections, with 2.9±1.4 injections in the first year of treatment. No patient developed GA enlargement in the area of MNV.

Conclusions : MNVs in GA showed different multimodal imaging features and therapeutic response in comparison to previously reported features of MNV in age-related macular degeneration (AMD) without GA. For these reasons, the combined phenotype (i.e. GA with neovascular AMD) should be considered as a distinct entity in the research and clinical setting.

This is a 2021 ARVO Annual Meeting abstract.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×